Maxim Group Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $4
Buy Rating Affirmed for Lucid Diagnostics Amidst Growth and Strategic Advances
CCORF Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $3
Lucid Diagnostics: Strong Buy Rating on Rising Test Volume and Promising Coverage Prospects
Lucid Diagnostics Analyst Ratings
Lucid Diagnostics: A Buy Rating Amidst Growing EsoGuard Test Volume and Anticipated Medicare Reimbursement
Lucid Diagnostics Analyst Ratings
Buy Rating Affirmed for Lucid Diagnostics Amid Positive Financial and Clinical Milestones
Lucid Diagnostics Analyst Ratings
Lucid Diagnostics (LUCD) Gets a Buy From Cantor Fitzgerald
Lucid Diagnostics: A Buy Rating on Operational Growth and Strategic Milestones
Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET), Jasper Therapeutics (JSPR) and Lucid Diagnostics (LUCD)
Lucid Diagnostics Analyst Ratings
Lucid Diagnostics: Strong Buy Rating With Significant Market Potential Despite Near-Term Losses
Lucid Diagnostics Analyst Ratings
Buy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement Path
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
Buy Rating for Lucid Diagnostics: Solid Test Volumes and Strategic Growth Initiatives Propel Market Position
Buy Rating Affirmed for Lucid Diagnostics Amid Strong Financials and Strategic Growth Initiatives
No Data